Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma
diluted 1: 10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID …

Infection with SARS-CoV-2 results in clinical outcomes ranging from silent or benign
infection in most individuals to critical pneumonia and death in a few. Genetic studies in …

Worldwide there have been over 760 million confirmed coronavirus disease 2019 (COVID-
19) cases, and over 13 billion COVID-19 vaccine doses have been administered as of April …

Life-threatening “breakthrough” cases of critical COVID-19 are attributed to poor or waning
antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting …

Autosomal inborn errors of type I IFN immunity and autoantibodies against these cytokines
underlie at least 10% of critical COVID-19 pneumonia cases. We report very rare …

Type I interferons (IFNs) have broad and potent antiviral activity. We review the interplay
between type I IFNs and SARS-CoV-2. Human cells infected with SARS-CoV-2 in vitro …

SARS-CoV-2 infections display tremendous interindividual variability, ranging from
asymptomatic infections to life-threatening disease. Inborn errors of, and autoantibodies …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the causative agent of
coronavirus disease 2019 (COVID‐19), has caused millions of deaths in the past two years …

Abstract SARS-CoV-2-reactive T cells are detected in some healthy unexposed individuals.
Human studies indicate these T cells could be elicited by the common cold coronavirus …

Background It is important to predict which patients infected by SARS-CoV-2 are at higher
risk of life-threatening COVID-19. Several studies suggest that neutralizing auto-antibodies …